retatrutide clinical trial effects fat loss results of once-weekly subcutaneous on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials Eli Lilly just released impressive – New GLP-3 drug significantly slashes

Quick reference: what does 20 units equal at every concentration This is the master reference

Balland, E

My ampoules are '1000 iu / 1 ml' so, by injecting the whole of the 1 ml from ampoule, I get 1,000 iu

Additionally, there are other vitamin B complex injections available as alternatives

Cholelithiasis (gallstones) was reported at low rates in the Phase 2 trial Incidence was slightly higher in higher-dose groups, though absolute numbers were small This observation is not unique to retatrutide semaglutide and tirzepatide trials also reported gallbladder events Cardiovascular Observations Heart rate changes were documented in clinical trial participants: Small mean increases in heart rate (2-4 bpm) were observed in active treatment groups This is consistent with GLP-1 agonist class effects semaglutide and tirzepatide produce similar heart rate increases No increased rate of major adverse cardiovascular events (MACE) was observed in Phase 2 TRIUMPH-4 is specifically designed to evaluate cardiovascular outcomes at scale Injection Site Reactions As a subcutaneous injectable, injection site reactions were reported: Injection site erythema, pain, and pruritus were documented at low rates Most injection site events were Grade 1 (mild) No injection site reactions led to treatment discontinuation in published data How Retatrutide Adverse Events Compare to Other GLP-1 Compounds Comparing adverse event profiles across different trials has significant limitations patient populations, dose ranges, and endpoint definitions vary